ADMA Biologics, Inc. (ADMA)
10.33
-0.03
(-0.29%)
USD |
NASDAQ |
Oct 12, 11:16
ADMA Biologics Free Cash Flow (Quarterly) : 27.28M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 27.28M |
| March 31, 2026 | 55.65M |
| December 31, 2025 | 34.36M |
| September 30, 2025 | -1.075M |
| June 30, 2025 | 18.61M |
| March 31, 2025 | -24.40M |
| December 31, 2024 | 47.47M |
| September 30, 2024 | 23.93M |
| June 30, 2024 | 43.28M |
| March 31, 2024 | -4.58M |
| December 31, 2023 | 16.19M |
| September 30, 2023 | 11.23M |
| June 30, 2023 | -6.931M |
| March 31, 2023 | -16.67M |
| December 31, 2022 | -11.13M |
| September 30, 2022 | -16.67M |
| June 30, 2022 | -16.77M |
| March 31, 2022 | -28.86M |
| December 31, 2021 | -37.14M |
| September 30, 2021 | -16.20M |
| June 30, 2021 | -36.74M |
| March 31, 2021 | -35.80M |
| December 31, 2020 | -35.82M |
| September 30, 2020 | -26.74M |
| June 30, 2020 | -25.45M |
| Date | Value |
|---|---|
| March 31, 2020 | -26.72M |
| December 31, 2019 | -21.25M |
| September 30, 2019 | -25.60M |
| June 30, 2019 | -18.76M |
| March 31, 2019 | -14.40M |
| December 31, 2018 | -19.61M |
| September 30, 2018 | -12.77M |
| June 30, 2018 | -15.41M |
| March 31, 2018 | -16.98M |
| December 31, 2017 | -15.37M |
| September 30, 2017 | -10.31M |
| June 30, 2017 | -8.868M |
| March 31, 2017 | -5.402M |
| December 31, 2016 | -3.624M |
| September 30, 2016 | -4.689M |
| June 30, 2016 | -4.845M |
| March 31, 2016 | -5.185M |
| December 31, 2015 | -4.074M |
| September 30, 2015 | -2.682M |
| June 30, 2015 | -4.454M |
| March 31, 2015 | -4.235M |
| December 31, 2014 | -3.459M |
| September 30, 2014 | -3.862M |
| June 30, 2014 | -4.555M |
| March 31, 2014 | -5.152M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Vericel Corp. | 14.26M |
| BioMarin Pharmaceutical, Inc. | 133.86M |
| Emergent BioSolutions, Inc. | 54.00M |
| Exelixis, Inc. | 300.92M |
| Akebia Therapeutics, Inc. | 2.446M |